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Background  The aims of this study were to quantify the risk and identify the 
causes of early postoperative mortality after total hip arthroplasty. This would 
help clinicians address preventable causes of death and help in accurate 
counseling and consenting of patients. 
Methods  We determined the death rate at 90 days in an unselected 
consecutive series of 1,727 primary total hip arthroplasties where patients had 
not routinely received chemothromboprophylaxis. 
Results  The mortality at 90 days was 17/1,727 (1%). The 90-day mortality was 
0.2% in patients under 70 years of age, 1.3% in patients between 70 and 80, and 
2.5% in those over 80. 7 patients died from ischemic heart disease, 4 died 
following cerebrovascular events, and 2 from pulmonary embolism. 4 patients 
died from non-vascular causes. Of the vascular deaths, ischemic heart disease 
outnumbered cerebrovascular events which, in turn, outnumbered pulmonary 
embolism (7 vs. 4 vs. 2). 
Interpretation  Strategies aimed at reducing deaths should address all vascular 
causes, not just pulmonary embolism. Our findings can be used to inform 
patients as to the risk of early death after total hip arthroplasty. 
 
Primary total hip arthroplasty (THA) carries a risk of early postoperative death. In 
early series, the death rate was 3–6% from pulmonary embolus alone (Coventry et 
al. 1974), a figure that is not acceptable for an operation designed to improve quality 
of life. Although previous studies have quantified the risk of death, to our knowledge, 
only one other study has stratified the risk of death in relation to age (Lie et al. 2002). 
The aims of this study were to determine the timing and cause of death following 
primary THA in current practice, to identify preventable deaths, to stratify the risk of 
death in relation to age, and to improve the quality of informed consent given to 
patients about to undergo THA. 
Patients and methods 
Over a 3-year period (1993–1996), 1,727 consecutive patients underwent primary 
THA at the Avon Orthopaedic Centre. The outcome was audited and patients who 
died within 90 days had their medical case notes, death certificates and post mortem 
reports examined. Retrieval at 90 days, with regards to death, was 100%. 
Results 
7 patients (0.41%) died within 30 days of their procedure and a further 10 (0.58%) 
died between day 30 and day 90, giving a total mortality rate at 90 days of 0.98% 
(17/1,727). 7 patients (0.41%) died from ischemic heart disease (IHD), 4 (0.23%) 
died following cerebrovascular events (CVE) and 2 (0.12%) died from pulmonary 
embolism (PE). 4 patients (0.23%) died from non-vascular causes (Table 1). 
Table 1.  Timing and causes of death in 17/1,727 patients within 90 days of primary 
THA 





CVE, cerebrovascular event; 
IHD, ischemic heart disease; 
PE, pulmonary embolism. 
F 83 0 IHD Yes 
F 80 2 IHD Yes 
M 72 8 IHD Yes 
F 75 17 Carcinoma No 
F 80 18 PE Yes 
F 89 20 IHD Yes 
F 79 25 PE Yes 
F 83 33 IHD No 
M 75 35 CVE No 
F 72 36 IHD No 
F 86 40 CVE Yes 
F 71 42 Peritonitis Yes 
M 78 47 Pneumonia No 
M 72 59 CVE No 
F 82 67 IHD No 
M 56 82 CVE Yes 
M 61 83 Carcinomatosis No 
The 90-day mortality was 2/822 (0.2%) in patients under 70 years of age, 8/626 
(1.3%) in patients between 70 and 80, and 7/279 (2.5%) in those over 80 (Table 2). 
Table 2. Death rates at 30 and 90 days after primary THA according to age at 
procedure 
Age (years) 30-day mortality 90-day mortality   
<70 0/882 (0%) 2/822 (0.2%)   
70–79 3/626 (0.5%) 8/626 (1.3%)   
80− 4/279 (1.4%) 7/279 (2.5%)   
Discussion 
In this study the death rate at 30 days was 0.41%. This compares with 0.91% in the 
Trent Arthroplasty Survey (Fender et al. 1997), 0.35% in the National Confidential 
Enquiry into Perioperative Deaths (NCEPOD) report (Campling 1993), an estimated 
60-day mortality of 0.8% seen in the Norwegian Hip Registry (Lie et al. 2000), 0.69% 
in the UK National Total Hip Replacement Outcome survey (Williams et al. 2002), 
and 0.48% in the Pulmonary Embolism Prevention (PEP) trial (2000). The PEP trial, 
however, includes both hip and knee replacements and is not strictly comparable. 
Our fatality rate from PE was 0.12%. This was without routine 
chemothromboprophylaxis. Mechanical thromboprophylaxis was employed. All 
patients wore thromboembolic deterrent (TED) stockings and a small proportion had 
AV impulse foot pumps. A trochanteric detachment approach to the hip was not used 
and a standard combined general and spinal anesthetic technique was employed. 
Without exception, this allowed mobilization of the patient within 48 h. 
The fatality rate from PE of 0.12% is average in contemporary studies. The 
highest rate reported (0.19%) was from the Trent Arthroplasty survey (Fender et al. 
1997) and the lowest (0.04%) was from the Oxford Record Linkage study (Seagroatt 
et al. 1991). The latter only recorded readmissions and may thus have missed deaths 
in the community. 
Informed consent can be obtained from patients before THA and the risk of death 
quantified, by using the age-stratified data given in Table 2 and the Figure. 
 
  
Vascular deaths (from CVE, IHD and PE) outnumbered non-vascular causes (13 
vs. 4). Of the vascular deaths, ischemic heart disease outnumbered cerebrovascular 
events which, in turn, outnumbered pulmonary embolism (7 vs. 4 vs. 2). Strategies 
aimed at reducing deaths should thus address all vascular causes, and not just PE. 
In a meta-analysis (1994), the antiplatelet trialists collaboration showed that 
using aspirin prophylaxis versus placebo caused a reduction in vascular deaths by 
one-sixth following non-cardiac surgery. The results of the PEP trial (2000) were 
comparable with this reduction, but unfortunately lacked the power to show this 
conclusively. In a different setting, using beta-blockers, deaths following noncardiac 
surgery were reduced from 14% to 3% in high-risk patients (Mangano et al. 1996). 
A power calculation based on the data from our study, with mortality from PE of 
0.12%, shows that a randomized controlled trial of chemoprophylaxis versus no 
chemoprophylaxis, using death as an outcome measure, would require 
approximately 24,000 patients in each group to show a 10% reduction in mortality 
(Maxwell 1990). Death following total hip arthroplasty is rare, and pulmonary embolus 
accounted for only 12% of deaths in this study. Further effort should be directed 
towards reducing the rate of death from preventable vascular causes. 
The risk of death after total hip arthroplasty increases dramatically with age. 
Patients and their families should be counselled accordingly. 
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